Index -
P/E 55.96
EPS (ttm) 2.43
Insider Own 2.60%
Shs Outstand 98.70M
Perf Week 3.02%
Market Cap 13.53B
Forward P/E 19.45
EPS next Y 6.99
Insider Trans -22.95%
Shs Float 96.92M
Perf Month -1.33%
Income 249.70M
PEG 3.11
EPS next Q 1.10
Inst Own 92.81%
Short Float 2.09%
Perf Quarter -4.33%
Sales 1.89B
P/S 7.17
EPS this Y 105.20%
Inst Trans -1.46%
Short Ratio 2.29
Perf Half Y 25.65%
Book/sh 22.61
P/B 6.01
EPS next Y 37.98%
ROA 8.71%
Short Interest 2.02M
Perf Year 32.39%
Cash/sh 10.37
P/C 13.12
EPS next 5Y 18.00%
ROE 12.68%
52W Range 89.04 - 148.37
Perf YTD 3.21%
Dividend Est. -
P/FCF 37.42
EPS past 5Y 62.04%
ROI 10.03%
52W High -8.34%
Beta 0.28
Dividend TTM -
Quick Ratio 2.40
Sales past 5Y 34.77%
Gross Margin 96.95%
52W Low 52.73%
ATR (14) 4.27
Dividend Ex-Date Dec 29, 1995
Current Ratio 2.45
EPS Y/Y TTM 57.90%
Oper. Margin 20.92%
RSI (14) 48.69
Volatility 3.16% 2.76%
Employees 1400
Debt/Eq 0.21
Sales Y/Y TTM 26.76%
Profit Margin 13.23%
Recom 1.68
Target Price 154.10
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 63.53%
Payout 0.00%
Rel Volume 0.81
Prev Close 137.76
Sales Surprise -0.64%
EPS Surprise 18.81%
Sales Q/Q 25.05%
Earnings May 01 BMO
Avg Volume 883.22K
Price 135.99
SMA20 -0.42%
SMA50 -0.35%
SMA200 12.21%
Trades
Volume 717,574
Change -1.28%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-24-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$140 → $170
Dec-13-23 Resumed
Citigroup
Neutral
$127
Dec-12-23 Initiated
Deutsche Bank
Buy
$136
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$135 → $140
Aug-21-23 Reiterated
Mizuho
Neutral
$112 → $113
Jul-24-23 Upgrade
SVB Securities
Market Perform → Outperform
$115 → $125
Jul-06-23 Upgrade
BMO Capital Markets
Underperform → Market Perform
$91 → $96
May-04-23 Upgrade
Guggenheim
Neutral → Buy
$145
Mar-30-23 Upgrade
Canaccord Genuity
Hold → Buy
$124 → $132
Mar-03-23 Upgrade
Evercore ISI
In-line → Outperform
$130
Feb-03-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$120 → $130
Nov-14-22 Downgrade
Evercore ISI
Outperform → In-line
$140 → $130
Oct-11-22 Initiated
UBS
Buy
$136
Sep-26-22 Initiated
Wells Fargo
Equal Weight
$110
Jun-06-22 Resumed
Jefferies
Buy
$126 → $112
Mar-03-22 Downgrade
Piper Sandler
Overweight → Neutral
$114 → $94
Feb-25-22 Upgrade
Goldman
Neutral → Buy
$115
Jan-18-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$122 → $90
Nov-19-21 Initiated
BMO Capital Markets
Underperform
$76
Nov-17-21 Upgrade
JP Morgan
Neutral → Overweight
$124
Show Previous Ratings
Apr-24-24 10:15AM
(Investor's Business Daily)
10:01AM
08:30AM
Apr-23-24 11:50AM
(Investor's Business Daily)
07:22AM
07:00AM
Loading…
07:00AM
Apr-22-24 11:10AM
Apr-16-24 04:01PM
02:30AM
Apr-10-24 04:01PM
Apr-09-24 07:37AM
Apr-03-24 08:30AM
Mar-28-24 08:30AM
Mar-24-24 09:19AM
Mar-23-24 08:00AM
(Investor's Business Daily)
08:00AM
Loading…
Mar-16-24 08:00AM
(Investor's Business Daily)
01:23AM
01:23AM
Mar-15-24 10:00AM
Mar-13-24 01:26AM
Mar-11-24 04:01PM
01:12PM
(Investor's Business Daily)
Mar-06-24 04:45PM
Mar-01-24 12:40AM
Feb-27-24 04:01PM
Feb-22-24 11:28PM
03:55AM
Feb-15-24 11:36PM
Feb-10-24 10:18AM
12:14AM
02:23AM
Loading…
Feb-09-24 02:23AM
Feb-08-24 09:13AM
12:20AM
(Thomson Reuters StreetEvents)
Feb-07-24 09:30AM
07:33AM
07:18AM
(Associated Press Finance)
07:00AM
Feb-05-24 09:16AM
Feb-02-24 11:02PM
Jan-31-24 10:00AM
Jan-24-24 11:02PM
06:54AM
Jan-22-24 09:38AM
Jan-17-24 04:16PM
Jan-12-24 09:35AM
Jan-11-24 09:02PM
Jan-10-24 09:24AM
Jan-05-24 02:02AM
Jan-02-24 04:01PM
Dec-26-23 06:56PM
07:22AM
Dec-25-23 08:23PM
Dec-20-23 04:54AM
Dec-16-23 01:01PM
Dec-15-23 02:30PM
Dec-12-23 03:05PM
Dec-10-23 11:15AM
Dec-09-23 11:05AM
Dec-06-23 03:01AM
Dec-05-23 04:01PM
Dec-02-23 05:06AM
Dec-01-23 07:00AM
Nov-30-23 05:04AM
Nov-13-23 06:07PM
07:00AM
Nov-09-23 04:01PM
Nov-08-23 04:05PM
04:01PM
Nov-06-23 09:45AM
Nov-02-23 08:30AM
Nov-01-23 06:34PM
Oct-31-23 09:30AM
08:32AM
08:15AM
07:05AM
(Associated Press Finance)
07:00AM
Oct-24-23 10:00AM
Oct-20-23 11:43AM
Oct-18-23 11:13AM
Oct-16-23 12:53PM
Oct-10-23 04:01PM
Oct-05-23 11:41AM
07:00AM
03:01AM
Oct-03-23 12:45PM
Sep-26-23 04:32PM
(Investor's Business Daily)
Sep-21-23 09:15AM
Sep-14-23 07:04PM
08:30AM
Sep-12-23 04:05PM
(Investor's Business Daily) +6.80%
12:18PM
07:30AM
Sep-11-23 07:01PM
08:30AM
Sep-06-23 08:00AM
(The Wall Street Journal)
Aug-31-23 04:01PM
Aug-29-23 08:30AM
Aug-28-23 08:30AM
Aug-27-23 08:53AM
Aug-18-23 04:34PM
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Option Exercise 81.21 19,818 1,609,431 53,365 Apr 17 05:19 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Sale 133.36 19,818 2,643,020 40,778 Apr 17 05:19 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Option Exercise 79.02 272 21,493 7,779 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Sale 137.30 272 37,346 7,507 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Option Exercise 103.52 5,000 517,600 12,507 Mar 25 06:02 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Sale 145.06 5,000 725,320 7,507 Mar 25 06:02 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Option Exercise 80.90 75,000 6,067,628 110,299 Mar 15 05:33 PM MORROW GEORGE J Director Mar 14 '24 Option Exercise 39.79 40,000 1,591,600 20,000 Mar 15 05:25 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Sale 139.38 75,000 10,453,417 40,778 Mar 15 05:33 PM MORROW GEORGE J Director Mar 14 '24 Sale 139.42 40,000 5,576,710 0 Mar 15 05:25 PM POPS RICHARD F Director Mar 13 '24 Option Exercise 42.76 23,200 992,032 52,712 Mar 15 05:19 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Option Exercise 106.02 3,000 318,060 10,507 Mar 15 05:15 PM POPS RICHARD F Director Mar 13 '24 Sale 140.33 23,200 3,255,621 29,512 Mar 15 05:19 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Sale 140.14 3,000 420,419 7,507 Mar 15 05:15 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Option Exercise 106.02 200 21,204 7,707 Mar 12 06:38 PM POPS RICHARD F Director Mar 11 '24 Option Exercise 42.76 100 4,276 29,612 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Sale 140.00 200 28,000 7,507 Mar 12 06:38 PM POPS RICHARD F Director Mar 11 '24 Sale 140.00 100 14,000 29,512 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Option Exercise 106.02 1,800 190,836 9,307 Mar 12 06:38 PM POPS RICHARD F Director Mar 08 '24 Option Exercise 42.76 1,700 72,692 31,212 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Sale 140.03 1,800 252,053 7,507 Mar 12 06:38 PM POPS RICHARD F Director Mar 08 '24 Sale 140.05 1,700 238,078 29,512 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Option Exercise 79.02 273 21,572 7,780 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Sale 135.51 273 36,994 7,507 Feb 29 07:02 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Option Exercise 53.67 75,000 4,025,043 93,759 Feb 29 06:55 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Option Exercise 79.02 6,544 517,107 10,007 Feb 29 07:02 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Sale 134.69 75,000 10,101,608 40,616 Feb 29 06:55 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Sale 135.34 6,544 885,638 7,507 Feb 29 07:02 PM Norwalk Leslie V Director Feb 27 '24 Option Exercise 84.95 8,000 679,600 8,000 Feb 29 06:50 PM Norwalk Leslie V Director Feb 27 '24 Sale 135.67 8,000 1,085,388 0 Feb 29 06:50 PM POPS RICHARD F Director Feb 20 '24 Option Exercise 12.98 15,000 194,700 44,512 Feb 22 05:11 PM POPS RICHARD F Director Feb 20 '24 Sale 132.47 15,000 1,987,047 29,512 Feb 22 05:11 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Option Exercise 39.28 5,090 199,951 512,052 Feb 14 05:17 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Sale 133.02 2,832 376,700 514,596 Feb 15 05:43 PM Boyer David W. Chief Corp. Affairs Officer Feb 13 '24 Sale 133.07 1,811 240,996 4,895 Feb 15 05:33 PM Onyia Jude Chief Scientific Officer Feb 13 '24 Sale 132.94 1,432 190,371 13,128 Feb 15 05:48 PM Gano Kyle Chief Business Development Off Feb 13 '24 Sale 132.89 1,352 179,674 135,166 Feb 15 05:40 PM ABERNETHY MATT Chief Financial Officer Feb 13 '24 Sale 132.85 1,352 179,612 31,528 Feb 15 05:27 PM ROBERTS EIRY Chief Medical Officer Feb 13 '24 Sale 132.96 1,114 148,122 23,716 Feb 15 05:51 PM BENEVICH ERIC Chief Commercial Officer Feb 13 '24 Sale 133.01 1,098 146,050 40,616 Feb 15 05:29 PM Lippoldt Darin Chief Legal Officer Feb 13 '24 Sale 132.99 1,098 146,028 39,740 Feb 15 05:45 PM Cooke Julie Chief Human Resources Officer Feb 13 '24 Sale 133.04 796 105,902 17,976 Feb 15 05:35 PM Delaet Ingrid Chief Regulatory Officer Feb 13 '24 Sale 133.03 716 95,253 7,507 Feb 15 05:38 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 08 '24 Sale 134.15 2,274 305,052 506,962 Feb 08 07:21 PM Cooke Julie Chief Human Resources Officer Feb 08 '24 Sale 135.44 1,329 179,995 17,263 Feb 08 07:35 PM Boyer David W. Chief Corp. Affairs Officer Feb 08 '24 Sale 135.41 1,328 179,830 4,895 Feb 08 07:46 PM ABERNETHY MATT Chief Financial Officer Feb 08 '24 Sale 134.21 980 131,529 30,314 Feb 08 07:12 PM ROBERTS EIRY Chief Medical Officer Feb 08 '24 Sale 134.21 980 131,522 22,717 Feb 08 07:28 PM Gano Kyle Chief Business Development Off Feb 08 '24 Sale 134.20 980 131,519 133,952 Feb 08 07:17 PM BENEVICH ERIC Chief Commercial Officer Feb 08 '24 Sale 134.19 980 131,509 39,631 Feb 08 07:15 PM Lippoldt Darin Chief Legal Officer Feb 08 '24 Sale 134.24 911 122,289 38,755 Feb 08 07:25 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 06 '24 Sale 142.18 3,040 432,218 504,919 Feb 08 07:21 PM Gano Kyle Chief Business Development Off Feb 06 '24 Sale 142.20 1,600 227,522 133,072 Feb 08 07:17 PM ABERNETHY MATT Chief Financial Officer Feb 06 '24 Sale 142.19 1,280 182,000 29,434 Feb 08 07:12 PM BENEVICH ERIC Chief Commercial Officer Feb 06 '24 Sale 142.12 1,280 181,910 38,751 Feb 08 07:15 PM Cooke Julie Chief Human Resources Officer Feb 06 '24 Sale 142.07 1,215 172,617 17,263 Feb 08 07:35 PM ROBERTS EIRY Chief Medical Officer Feb 06 '24 Sale 142.24 1,121 159,446 21,837 Feb 08 07:28 PM Lippoldt Darin Chief Legal Officer Feb 06 '24 Sale 142.17 1,041 147,995 37,939 Feb 08 07:25 PM Boyer David W. Chief Corp. Affairs Officer Feb 06 '24 Sale 141.96 456 64,734 4,894 Feb 08 07:46 PM Delaet Ingrid Chief Regulatory Officer Feb 01 '24 Sale 139.77 623 87,077 6,865 Feb 02 07:14 PM GORMAN KEVIN CHARLES Chief Executive Officer Jan 31 '24 Sale 140.69 2,707 380,845 502,188 Feb 02 07:21 PM Boyer David W. Chief Corp. Affairs Officer Jan 31 '24 Sale 140.80 2,096 295,115 4,894 Feb 02 07:07 PM Cooke Julie Chief Human Resources Officer Jan 31 '24 Sale 141.29 1,740 245,842 17,263 Feb 02 07:11 PM Gano Kyle Chief Business Development Off Jan 31 '24 Sale 140.70 1,541 216,813 131,635 Feb 02 07:17 PM ROBERTS EIRY Chief Medical Officer Jan 31 '24 Sale 140.79 1,457 205,132 20,832 Feb 02 07:29 PM ABERNETHY MATT Chief Financial Officer Jan 31 '24 Sale 140.72 1,283 180,539 28,284 Feb 02 07:00 PM Lippoldt Darin Chief Legal Officer Jan 31 '24 Sale 140.65 1,250 175,810 37,005 Feb 02 07:24 PM BENEVICH ERIC Chief Commercial Officer Jan 31 '24 Sale 140.78 1,207 169,927 37,601 Feb 02 07:05 PM Delaet Ingrid Chief Regulatory Officer Jan 31 '24 Sale 141.94 422 59,899 6,309 Feb 02 07:14 PM Onyia Jude Chief Scientific Officer Jan 31 '24 Sale 141.94 126 17,884 11,843 Feb 02 07:26 PM Lippoldt Darin Chief Legal Officer Jan 22 '24 Option Exercise 79.02 10,000 790,200 45,882 Jan 24 05:47 PM Lippoldt Darin Chief Legal Officer Jan 22 '24 Sale 139.86 10,000 1,398,553 35,882 Jan 24 05:47 PM GORMAN KEVIN CHARLES Chief Executive Officer Jan 09 '24 Option Exercise 19.59 62,023 1,215,031 561,777 Jan 10 04:31 PM GORMAN KEVIN CHARLES Chief Executive Officer Jan 09 '24 Sale 134.01 62,023 8,311,895 499,754 Jan 10 04:31 PM GORMAN KEVIN CHARLES Chief Executive Officer Jan 08 '24 Option Exercise 19.59 105,835 2,073,308 605,589 Jan 10 04:31 PM GORMAN KEVIN CHARLES Chief Executive Officer Jan 08 '24 Sale 132.44 105,835 14,016,523 499,754 Jan 10 04:31 PM Gano Kyle Chief Business Development Off Jan 02 '24 Option Exercise 19.59 75,000 1,469,250 199,134 Jan 04 06:32 PM RASTETTER WILLIAM H Director Jan 02 '24 Option Exercise 12.98 20,000 259,600 62,785 Jan 04 06:26 PM Gano Kyle Chief Business Development Off Jan 02 '24 Sale 131.47 75,000 9,860,194 130,250 Jan 04 06:32 PM RASTETTER WILLIAM H Director Jan 02 '24 Sale 131.47 11,044 1,451,927 51,741 Jan 04 06:26 PM Cooke Julie Chief Human Resources Officer Dec 22 '23 Option Exercise 73.04 24,000 1,752,900 31,263 Dec 27 04:08 PM Cooke Julie Chief Human Resources Officer Dec 22 '23 Sale 128.66 24,000 3,087,808 17,263 Dec 27 04:08 PM LYONS GARY A Director Dec 22 '23 Sale 130.04 10,000 1,300,443 193,697 Dec 27 04:10 PM ROBERTS EIRY Chief Medical Officer Dec 22 '23 Sale 126.74 10,000 1,267,448 19,521 Dec 27 04:15 PM ROBERTS EIRY Chief Medical Officer Dec 12 '23 Option Exercise 81.05 13,925 1,128,621 36,499 Dec 14 05:22 PM ROBERTS EIRY Chief Medical Officer Dec 12 '23 Sale 120.30 13,925 1,675,240 29,521 Dec 14 05:22 PM ROBERTS EIRY Chief Medical Officer Dec 08 '23 Option Exercise 81.05 300 24,315 29,721 Dec 11 06:18 PM ROBERTS EIRY Chief Medical Officer Dec 08 '23 Sale 120.10 300 36,031 29,521 Dec 11 06:18 PM ROBERTS EIRY Chief Medical Officer Dec 07 '23 Option Exercise 78.52 77,379 6,076,120 68,243 Dec 11 06:18 PM ROBERTS EIRY Chief Medical Officer Dec 07 '23 Sale 120.37 77,379 9,314,319 29,521 Dec 11 06:18 PM Lippoldt Darin Chief Legal Officer Dec 06 '23 Option Exercise 43.24 20,830 900,689 56,712 Dec 08 06:23 PM ROBERTS EIRY Chief Medical Officer Dec 06 '23 Option Exercise 77.81 8,396 653,293 37,917 Dec 08 07:09 PM Lippoldt Darin Chief Legal Officer Dec 06 '23 Sale 119.86 20,830 2,496,648 35,882 Dec 08 06:23 PM ROBERTS EIRY Chief Medical Officer Dec 06 '23 Sale 120.03 8,396 1,007,780 29,521 Dec 08 07:09 PM LYONS GARY A Director Dec 01 '23 Option Exercise 12.98 5,000 64,900 208,697 Dec 05 04:54 PM LYONS GARY A Director Dec 01 '23 Sale 116.77 5,000 583,837 203,697 Dec 05 04:54 PM Onyia Jude Chief Scientific Officer Nov 29 '23 Sale 113.57 2,331 264,733 11,732 Dec 01 05:41 PM Lippoldt Darin Chief Legal Officer Nov 27 '23 Sale 112.27 10,919 1,225,911 35,882 Nov 29 04:36 PM Boyer David W. Chief Corp. Affairs Officer Oct 02 '23 Sale 112.68 1,437 161,921 4,894 Oct 04 05:07 PM LYONS GARY A Director Sep 12 '23 Option Exercise 12.98 5,000 64,900 208,697 Sep 14 04:51 PM
Index RUT
P/E -
EPS (ttm) -2.10
Insider Own 2.72%
Shs Outstand 61.00M
Perf Week 8.71%
Market Cap 1.22B
Forward P/E -
EPS next Y -2.94
Insider Trans -8.09%
Shs Float 59.46M
Perf Month -10.88%
Income -126.09M
PEG -
EPS next Q -0.83
Inst Own 102.60%
Short Float 10.46%
Perf Quarter -0.50%
Sales 168.34M
P/S 7.25
EPS this Y -66.34%
Inst Trans -2.45%
Short Ratio 8.75
Perf Half Y 12.63%
Book/sh 10.96
P/B 1.82
EPS next Y 15.08%
ROA -14.02%
Short Interest 6.22M
Perf Year -25.72%
Cash/sh 9.71
P/C 2.06
EPS next 5Y -
ROE -18.06%
52W Range 16.49 - 28.96
Perf YTD -5.89%
Dividend Est. -
P/FCF 18.32
EPS past 5Y -9.81%
ROI -16.98%
52W High -31.01%
Beta 0.79
Dividend TTM -
Quick Ratio 7.36
Sales past 5Y 70.11%
Gross Margin 93.17%
52W Low 21.16%
ATR (14) 0.96
Dividend Ex-Date -
Current Ratio 7.36
EPS Y/Y TTM -127.34%
Oper. Margin -81.54%
RSI (14) 46.87
Volatility 5.39% 4.13%
Employees 280
Debt/Eq 0.12
Sales Y/Y TTM 2.28%
Profit Margin -74.90%
Recom 1.46
Target Price 35.83
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -56.17%
Payout -
Rel Volume 0.53
Prev Close 19.23
Sales Surprise -42.44%
EPS Surprise -192.45%
Sales Q/Q 106.80%
Earnings Feb 27 AMC
Avg Volume 711.00K
Price 19.98
SMA20 -1.17%
SMA50 -9.21%
SMA200 -4.59%
Trades
Volume 375,500
Change 3.90%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Reiterated
BTIG Research
Buy
$56 → $38
Feb-28-24 Downgrade
Piper Sandler
Overweight → Neutral
$37 → $24
May-19-23 Initiated
BofA Securities
Buy
$42
Dec-06-22 Initiated
Cowen
Outperform
Oct-13-22 Upgrade
Raymond James
Outperform → Strong Buy
$58
Sep-21-22 Initiated
JP Morgan
Overweight
$37
Jul-06-22 Resumed
Canaccord Genuity
Buy
$50
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$54
Jan-21-22 Initiated
SMBC Nikko
Outperform
$60
Dec-15-21 Initiated
H.C. Wainwright
Buy
$61
Oct-15-21 Resumed
BTIG Research
Buy
$56
Feb-24-21 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Mar-04-20 Initiated
Barclays
Underweight
$28
Feb-25-20 Upgrade
Guggenheim
Neutral → Buy
$43
Jan-30-20 Initiated
RBC Capital Mkts
Outperform
$44
Nov-20-19 Resumed
Guggenheim
Neutral
Aug-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-07-19 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Initiated
Mizuho
Buy
Apr-12-19 Initiated
Guggenheim
Buy
Show Previous Ratings
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
Feb-28-24 04:01PM
09:35AM
(Thomson Reuters StreetEvents)
08:38AM
Loading…
08:38AM
Feb-27-24 05:20PM
04:39PM
04:26PM
(Associated Press Finance)
04:01PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
Jan-03-24 04:01PM
09:55AM
08:01AM
Loading…
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
(FierceBiotech.com) -7.01%
Nov-07-23 04:39PM
(Associated Press Finance)
04:01PM
04:01PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
12:00PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
Sep-27-23 09:01AM
Sep-19-23 04:01PM
06:01AM
Loading…
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:08PM
04:01PM
May-01-23 04:01PM
Apr-26-23 08:00PM
08:01AM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
02:56AM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
04:01PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
10:00AM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
09:55AM
09:01AM
Nov-07-22 05:25PM
04:01PM
04:01PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Oct-05-22 08:01AM
Sep-09-22 08:01AM
Aug-29-22 06:35AM
Aug-03-22 05:25PM
04:01PM
Aug-02-22 06:30AM
Aug-01-22 11:31AM
Jul-27-22 04:01PM
Jul-01-22 11:59AM
May-26-22 05:01PM
May-13-22 09:18AM
May-07-22 09:30AM
May-06-22 10:24AM
05:38AM
May-05-22 05:25PM
04:01PM
11:26AM
11:12AM
11:07AM
09:31AM
08:45AM
May-04-22 10:52AM
May-03-22 07:55AM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dahiyat Bassil I PRESIDENT & CEO Mar 11 '24 Sale 23.50 2,741 64,418 351,894 Mar 12 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 11 '24 Sale 23.50 1,280 30,082 186,433 Mar 12 04:05 PM Eckert Celia SVP, GENERAL COUNSEL Mar 11 '24 Sale 23.50 850 19,977 45,465 Mar 12 04:06 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 11 '24 Sale 23.50 849 19,953 121,070 Mar 12 04:08 PM GUSTAFSON KURT A Director Mar 06 '24 Option Exercise 10.73 15,000 160,950 20,007 Mar 07 04:10 PM GUSTAFSON KURT A Director Mar 06 '24 Sale 23.18 14,000 324,453 6,007 Mar 07 04:10 PM Dahiyat Bassil I PRESIDENT & CEO Mar 05 '24 Sale 23.43 12,528 293,519 300,097 Mar 07 04:01 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 05 '24 Sale 23.43 6,629 155,311 166,989 Mar 07 04:05 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 05 '24 Sale 23.43 4,474 104,821 121,919 Mar 07 04:07 PM Eckert Celia SVP, GENERAL COUNSEL Mar 05 '24 Sale 23.43 3,892 91,186 33,226 Mar 07 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 14 '24 Option Exercise 11.05 11,943 131,970 173,618 Feb 16 04:06 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Option Exercise 11.05 68,057 752,030 215,783 Feb 14 02:23 PM GORMAN KEVIN CHARLES Director Feb 13 '24 Buy 19.12 53 1,013 5,060 Feb 15 04:02 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Sale 19.38 54,108 1,048,743 161,675 Feb 14 02:23 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Option Exercise 11.05 65,001 718,261 357,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Sale 20.93 45,000 941,670 312,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Option Exercise 4.25 76,012 323,051 325,713 Jun 22 08:33 AM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Sale 26.19 33,497 877,286 292,216 Jun 22 08:33 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite